Arabic Arabic English English French French German German
dark

Public Meeting: Patient-Focused Drug Development for Hereditary Angioedema (Part 1 of 2)

On September 25, 2017, FDA hosted a public meeting on Patient-Focused Drug Development for Hereditary Angioedema. FDA was interested in obtaining patient and caregiver perspectives on the impact of Hereditary Angioedema on daily life and patient views on treatment approaches. For more information, visit the meeting webpage: https://go.usa.gov/xANw9

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Public Meeting: Patient-Focused Drug Development for Hereditary Angioedema (Part 2 of 2)

Next Post

Smart Antibacterial Avoids Collateral Damage, Potential Blowback

Related Posts
Total
0
Share